US EditionNovo Nordisk CEO Jorgensen to Leave After Fall in Share Price
- Novo Nordisk revealed that its chief executive, Lars Fruergaard Jorgensen, is set to depart following ongoing market difficulties and a significant drop in the company's share value in 2025.
- The departure follows rising competition from Eli Lilly’s obesity drug Zepbound, which has surpassed Novo’s Wegovy in U.S. Prescriptions since mid-March 2025.
- Under Jorgensen’s eight-year tenure, Novo Nordisk led the obesity drug market with strong sales of Wegovy and Ozempic and became Europe’s most valuable listed company.
- Since reaching an all-time high in June 2024, Novo Nordisk’s shares fell 59%, trading 3% lower on the CEO news, with the board citing that succession serves shareholders’ best interests.
- Jorgensen will remain as CEO until a successor is named, and the leadership change reflects Novo’s response to ongoing market pressures and a declining first-mover advantage.
Insights by Ground AI
Does this summary seem wrong?
104 Articles
104 Articles
All
Left
17
Center
37
Right
12
Novo Nordisk, the Ceo Resigns After the Collapse on the Stock Exchange: -50% in 12 Months (Two Years Ago She Was the Queen of Europe)
In 2023 the Danish pharmaceutical giant had become the largest European company by market capitalisation, surpassing the French luxury group Lvmh
·Italy
Read Full Article
Coverage Details
Total News Sources104
Leaning Left17Leaning Right12Center37Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 26%
C 56%
R 18%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
